Lilly's Weight-Loss Shot Lands on Hims & Hers, Plus Marvell's $115B Bet | Tech Arcade Podcast
Eli Lilly's Zepbound and Foundayo can now be bought directly on Hims & Hers, at the same self-pay prices Lilly charges, and Hims shares jumped more than 7% premarket. Then, why Marvell is paying about $115 billion in stock for laser maker Lumentum, and why both stocks fell.
Full story: https://www.techarcade.io/eli-lilly-just-put-its-299-weight-loss-shot-straight-on-hims-hers-and-the-stock-popped-7/
Full story: https://www.techarcade.io/marvell-is-paying-115-billion-to-bet-that-ai-data-centers-run-on-light/
Sources
https://www.prnewswire.com/news-releases/lilly-and-hims--hers-expand-access-to-fda-approved-lilly-medicines-302931979.html
https://www.investing.com/news/stock-market-news/lilly-to-sell-obesity-drugs-directly-on-hims--hers-site-5008115
https://www.sec.gov/Archives/edgar/data/0001633978/000119312526442758/d163169dex991.htm
https://techcrunch.com/2026/11/02/in-one-of-the-largest-deals-in-tech-history-marvell-buys-lumentum-for-115b/
https://www.fool.com/investing/2026/11/02/why-lumentum-stock-fell-14-9-today/
Note: reported sizes of the 2 November drops in Marvell and Lumentum shares differ between sources, so the episode does not give a figure.
More at https://www.techarcade.io
#techarcade #elililly #himsandhers #marvell #lumentum


